SUAB0408 | STUDY OF THE VIROLOGICAL EFFICACY OF DOLUTEGRAVIR-BASED COMBINATIONS DURING FOLLOW-UP OF HIV- PATIENTS IN ABIDJAN (CÔTE D’IVOIRE)

Jean-Jacques Renaud Dechi¹, Thomas D’Aquin Toni², Jean-Louis Philippe N’Din¹, Aya Jeanne Armande Ake¹, Tossea Stéphane Koui¹, Leto Olivier Gogbe², Saydou Kabore¹, Kpadraux Danielle Odegue⁴, Amedee Junior Wawa², Armand Yao¹, Massara Camara-Cisse³, Kouabla Liliane Siransy², Henri Chenal², Bamory Dembele¹, Yassongui Mamadou Sekongo¹ | ¹Entre National de Transfusion Sanguine de Côte d’Ivoire (CNTSCI), Abidjan, Côte d’Ivoire; ²Centre Intégré de Recherches Biocliniques d’Abidjan (CIRBA), Abidjan, Côte d’Ivoire; ³Laboratoire de Biochimie-UFR-Sciences Médicales-UFHB, Abidjan, Côte d’Ivoire; ⁴Plateforme de biologie moléculaire, Institut Pasteur, Abidjan, Côte d’Ivoire

In the aftermath of the implementation of dolutegravir (DTG)-based triple therapy, it is imperative to meticulously monitor the efficacy of these therapeutic protocols. The objective of the present study was to evaluate the virological impact of DTG-based triple therapy during the follow-up of HIV-1-infected patients in Abidjan (Côte d’Ivoire). This cross-sectional study was conducted between January 2023 and December 2024. The study population included HIV-1-infected patients on DTG-based tritherapy who received follow-up care at CIRBA and underwent two viremia measurements. The biological analyses comprised the quantification of plasma HIV-1 viral RNA. The technique employed was the one developed by Roche on the Cobas 4800 (Roche Diagnostics, Mannheim, Germany), with a threshold of 20 copies/mL. Viremia levels were classified into three categories, namely virological failure (CV ≥ 1000 copies/mL), detectable viremia (CV between 20 and 1000 copies/mL), and undetectable viremia (CV < 20 copies/mL). Statistical analyses were performed using Excel and SPSS software. The analysis of 1405 patient samples was conducted. The median age recorded was 49 years (interquartile range: 2-82 years). The majority of patients were female (60%; n = 843/1405). Patients had their viremia measured on two separate occasions. At the initial measurement, 9% (n=126/1405) had failed virological therapy, 18% (n=258/1405) had detectable viremia, and 73% (n=1021/1405) had undetectable viremia. The rate of patients on DTG+3TC+ABC was 9.5% (n=133/1405), 0.3% (n=4/1405) on DTG+3TC+AZT and 90.2% (n=1268/1405) on DTG+3TC+TDF. The median time interval between the two measurements was 11 months [3-22]. At the second measurement, 3% (n=43/1405) exhibited virological failure, 20% (n=281/1405) demonstrated detectable viremia, and 77% (n=1081/1405) exhibited undetectable viremia. The rate of patients on DTG+3TC+ABC was 11.7% (n=165/1405), 0.4% (n=5/1405) on DTG+3TC+AZT and 87.9% (n=1235/1405) on DTG+3TC+TDF. Conclusions and recommendations: The present study corroborated the efficacy of DTG-based triple therapy in HIV-1-infected patients. However, the study revealed that a proportion of patients exhibited detectable viremia and virological failure. It is imperative to establish a framework for the initiation of DTG-based treatment, encompassing the quantification of plasma viral RNA and genotypic resistance testing, to ensure optimal virological monitoring.